[Recent Advances in SARS-CoV-2-Induced Immune Thrombocytopenia --Review]

Xin-Hui Zhou1, Chang-Geng Ruan1, Yang He2

  • 1Department of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.

Summary

SARS-CoV-2-induced immune thrombocytopenia (ITP) is an autoimmune condition following COVID-19. Treatment requires careful consideration due to bleeding and thrombosis risks, with specific therapies reserved for severe cases.